Oct 2026· Cerrahpasa Medical Journal· Vol 50, pp. 1-7· 0 citations· 22 references
TL;DR
Findings provide real-world evidence to guide clinical management of these rare malignancies and show complete resection remains the cornerstone of survival in TETs.
Abstract
Objective: Thymic epithelial tumors (TETs), including thymomas and thymic carcinomas, are rare mediastinal cancers with distinct prognoses, and long-term real-world data on survival and prognostic factors remain limited.
Methods: In this retrospective single-center study, 42 patients diagnosed between 2006 and 2024 were analyzed. Data on clinicopathological features, treatments, and survival were obtained from records. Survival was assessed using the Kaplan–Meier method with the log-rank test, and prognostic factors were evaluated using univariable Cox proportional hazards regression analysis.
Results: The median follow-up duration was 38 months (range, 2-197 months). The median age at diagnosis was 52 years. Thymoma accounted for 81% of cases and thymic carcinoma for 19%. Complete resection (R0) was achieved in 67.7% of operated patients and was strongly associated with better survival, with a 5-year overall survival (OS) of 94% compared to 33% in incompletely resected tumors. De novo metastatic disease (hazards ratio [HR] = 15.3; 95% CI: 3.39-69.20) and R2 resection (HR = 8.64; 95% CI: 2.65-28.18) were significantly associated with poorer OS. No statistically significant difference in survival was observed between patients who received mediastinal radiotherapy and those who did not.
Conclusions: Complete resection remains the cornerstone of survival in TETs. Metastatic and incomplete resection are associated with poor outcomes. No statistically significant difference in survival was observed between patients who received mediastinal radiotherapy and those who did not. These findings provide real-world evidence to guide clinical management of these rare malignancies.
Cite this article as: Türkoğlu E, Işık D, Buser NS, et al. Prognostic factors and survival in thymoma and thymic carcinoma: a retrospective cohort study. Cerrahpaşa Med J 2026, 50, 0089, doi: 10.5152/cjm.2026.26089.
This real-world CUP cohort shows patients with favorable risk groups have better survival outcomes than unfavorable risk groups, with survival comparable to specialized international series.
L. Thongthieang· Journal of the Medical Assoc...· 0 citations
Background and Objectives: Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a rare malignancy, accounting for approximately 2–3.5% of surgically resected primary lung cancers. Given its rarity, pLCNEC has been less extensively studied than other, more common lung cancer subtypes. In this study, we evaluated an...
Yeşim Özufacık Bölükbaşı, Aydın Aytekin· Medicina· 0 citations
Aim: Leptomeningeal metastasis (LM) from breast cancer carries a poor prognosis, and most published cohorts originate from high-volume referral centers. We aimed to identify factors associated with overall survival (OS) after an LM diagnosis in routine practice and to describe diagnostic and treatment patterns.Methods:...
Mehmet Mutlu Kıdı, Omer Kaya, Sedat Biter et al.· Cukurova Anestezi ve Cerrahi...· 0 citations
Objective: Small cell carcinomas of the kidney (SCCK) and the upper urinary tract (SCC UUT) are exceedingly rare and aggressive malignancies. This study aimed to compare survival outcomes of these two conditions using a large population-based database.Materials and Methods: Data from the Surveillance, Epidemiology, and...
Y. Aktaş, M. Gelmiş· Meandros Medical and Dental...· 0 citations
Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (...
R. Pinninti, K. Subramaniyan, R. Iyer et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.